Benjamin L Wolozin, 6727 Placid Rd, Newton, MA 02459

6472421, Oct 29, 2002

Nov 13, 1998

09/190439

Benjamin Wolozin - Hinsdale IL

Nymox Corporation - St. Laurent

A61K 3135

514451, 514455, 514510, 514543

Described are methods for treating, preventing, or reducing the risk of the onset of Alzheimers disease by administering a therapeutically effective amount of an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (âHMG CoA reductase inhibitorâ) to a patient who is at risk for a coronary or cerebrovascular event or at risk for Alzheimers disease.

6780971, Aug 24, 2004

Jul 9, 2001

09/901187

Benjamin Wolozin - Hinsdale IL
Michael S. Lebowitz - Baltimore MD

Panacea Pharmaceuticals, Inc. - Gaithersburg MD

A01K 3804

530329, 514 2, 514 16

The present invention provides methods of determining aggregation of -synuclein, which are a hallmark of Lewy body diseases such as Parkinsons disease. Also disclosed are inhibitors of the aggregation, including magnesium and -synuclein binding peptides. The inhibitors are useful in the treatment of Lewy body diseases.

7605133, Oct 20, 2009

Jul 30, 2004

10/909116

Benjamin Wolozin - Hinsdale IL, US
Michael S. Lebowitz - Baltimore MD, US

Panacea Pharmaceuticals, Inc. - Gaithersburg MD

A61K 38/08
C07K 7/06
C07K 9/00

514 16, 530329

The present invention relates to drug screening methods and methods of preventing neural tissue damage caused by α-synuclein aggregation. These methods are especially useful in the design and development of inhibitors of Lewy body diseases and other synucleinopathies, and further useful in the treatment of such neurodegenerative diseases, particularly Parkinson's Disease.

2003003, Feb 20, 2003

Dec 23, 1997

08/997464

DAVID STERN - GREAT NECK NY, US
SHI DU YAN - NEW YORK NY, US
BENJAMIN WOLOZIN - HINSDALE IL, US

A61K049/00
A01K067/00

800/003000, 800/008000

This invention provides a method for evaluating the ability of a compound to inhibit neurotoxicity which comprises (a) contacting a cell which expresses a receptor for advanced glycation end product protein and a mutant presenilin-2 protein in a cell culture and the compound; (b) determining the level of cell death in the cell culture; and (c) comparing the level of cell death determined in step (b) with the amount determined in the absence of the compound so as to evaluate the ability of the compound to inhibit neurotoxicity. The invention also provides a method for evaluating the ability of a compound to inhibit binding of an amyloid- peptide to a receptor for advanced glycation end product which comprises (a) contacting a cell which expresses a mutant presenilin-2 protein and a receptor for advanced glycation end product protein with amyloid- protein and the compound; (b) determining the amount of amyloid- peptide bound to the cell; (c) comparing the amount of bound amyloid- peptide determined in step (b) with the amount determined in the absence of the compound so as to evaluate the ability of the compound to inhibit binding of the amyloid- peptide to the receptor for advanced glycation end product. The invention also provides a transgenic non-human animal whose somatic and germ cells express mutant human presenilin-2 protein and human receptor for advanced glycation end product protein.

2005014, Jul 7, 2005

Nov 4, 2004

10/980180

Benjamin Wolozin - Newton MA, US
James Sellers - Fort Pierce FL, US

A01K067/033

800013000

A novel method of generating a sterile marine organism is disclosed. The method of generating sterile wild type and transgenic marine organisms having triploid genomes is also disclosed. Specifically, we disclose methods of inducing sterility in a number of fish and other species such that their progeny cannot produce offspring by breeding organisms with tetraploid genomes to organisms with diploid genomes to produce triploid offspring.

2014008, Mar 20, 2014

May 21, 2012

14/118628

Benjamin WOLOZIN - Newton MA, US
Benjamin Wolozin - Newton MA, US

C07D 487/04
A61K 31/704
A61K 31/365
C07D 417/04
C07D 401/12
C07D 211/34
C07D 401/04
C07D 215/36
C07D 207/36
C07D 239/52
C07D 211/52
C07D 239/94
C07D 215/227
C07D 403/06
G01N 33/50

514 33, 435375, 435325, 435 29, 514468, 514470, 514321, 514323, 514331, 514318, 514267, 514312, 514422, 514269, 514327, 5142664, 514221, 514218

Herein, methods of modulating inclusion formation and stress granules in cells are described. The methods comprise contacting a cell with an inclusion inhibitor. Methods for screening for modulators of TDP-43 aggregation are also described.

5811310, Sep 22, 1998

Dec 23, 1994

8/362783

Hossein A. Ghanbari - Lake Forest IL
Peter Davies - Rye NY
Benjamin Wolozin - Columbia MD

Albert Einstein College of Medicine of Yeshiva Univ. - Bronx NY

G01N 3353

436518

The invention relates to an antigen associated with Alzheimer's disease and to antibodies specific for said antigen. This invention further relates to methods for diagnosing Alzheimer's disease utilizing assays containing Alzheimer's associated antigen, antibodies specific for said antigen and samples from an individual suspected of having Alzheimer's disease.

5869266, Feb 9, 1999

Oct 30, 1990

7/605788

Benjamin L. Wolozin - Columbia MD
Hayden G. Coon - Gaithersburg MD

The United States of America as represented by the Department of Health
and Human Services - Washington DC

G01N 3353

435 721

The present invention relates to a culture of human olfactory neurons. The neurons may display a normal neuronal pathology or a pathology characteristic of a generalized central nervous system disease. The cultured neurons can be used for neurotoxicity tests, screening for therapeutic drugs and anti-viral agents, and diagnosing Alzheimer's disease.